Area of research
Epidemiology · Infectious Diseases
Research interest
Research interests include Respiratory viral infections research, Pneumonia and Respiratory Infections, Influenza Virus Research Studies, and COVID-19 Clinical Research Studies.
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus.
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years.
RSV Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345.
Detection by Nasopharyngeal Swabs Alone Underestimates Respiratory Syncytial Virus-Related Hospitalization Incidence in Adults: The Multispecimen Study's Final Analysis.
Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review.
Burden and severity of respiratory syncytial virus infection in adults with cardiovascular diseases: A systematic literature review
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Adult Vaccine Coadministration Is Safe, Effective, and Acceptable: Results of a Survey of the Literature.
Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data
Neurologic Complications of Influenza and Potential Protective Vaccine Effects.
Respiratory Syncytial Virus Risk Assessment in Adults: Implications for Vaccine Recommendations Beyond Age.
Clinical Features and Gene Expression Patterns in Adults Hospitalized With Respiratory Syncytial Virus and Human Metapneumovirus Infection.
A four-gene signature from blood to exclude bacterial etiology of lower respiratory tract infection in adults.
Assessment of Illness Severity in Adults Hospitalized With Acute Respiratory Tract Infection due to Influenza, Respiratory Syncytial Virus, or Human Metapneumovirus.
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Adult Vaccine Coadministration Is Safe, Effective, and Acceptable: Results of A Literature Review
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
A systems genomics approach uncovers molecular associates of RSV severity.
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults